Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2012

Open Access 01-06-2012 | Research Article

PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET

Authors: Guus A. M. S. van Dongen, Alex J. Poot, Danielle J. Vugts

Published in: Tumor Biology | Issue 3/2012

Login to get access

Abstract

During the last decade, the discovery of critical tumor targets has boosted the design of targeted therapeutic agents with monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) receiving most of the attention. Immuno-positron emission tomography (immuno-PET) and TKI-PET, the in vivo tracking and quantification of mAbs and TKIs biodistribution with PET, are exciting novel options for better understanding of the in vivo behavior and efficacy of these targeted drugs in individual patients and for more efficient drug development. Very recently, current good manufacturing practice compliant procedures for labeling of mAbs with positron emitters have been described, as well as the preparation of some radiolabeled TKIs, while the first proof of principle studies has been performed in patients. In this review, technical developments in immuno-PET and TKI-PET are described, and their clinical potential is discussed. An overview is provided for the most appealing preclinical immuno-PET and TKI-PET studies, as well as the first clinical achievements with these emerging technologies.
Literature
1.
2.
Mano M. The burden of scientific progress: growing inequalities in the delivery of cancer care. Acta Oncol. 2006;45:84–6.PubMedCrossRef
3.
Van Dongen GAMS, Visser GWM, Lub-de Hooge MN, De Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007;12:1379–89.PubMedCrossRef
4.
Van Dongen GAMS, Vosjan MJWD. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm. 2010;25:375–85.PubMedCrossRef
5.
Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol. 2010;11:992–1000.PubMedCrossRef
6.
7.
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280–90.PubMedCrossRef
8.
Tijink BM, Buter J, De Bree R, Giaccone G, Lang MS, Staab A, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006;12:6064–72.PubMedCrossRef
9.
Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28:3965–72.PubMedCrossRef
10.
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:3076–83.PubMedCrossRef
11.
Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser GWM, Kloet RW, et al. 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging. 2009;36:1235–44.PubMedCrossRef
12.
Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, Van Dongen GAMS. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271–81.PubMed
13.
Nayak TK, Brechbiel MW. Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug Chem. 2009;20:825–41.PubMedCrossRef
14.
Tolmachev V, Stone-Elander S. Radiolabelled proteins for positron emission tomography: pros and cons of labelling methods. Biochim Biophys Acta. 2010;1800:487–510.PubMedCrossRef
15.
Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Mol Imaging. 2010;9:1–20.PubMed
16.
Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729–39.PubMedCrossRef
17.
Walter M, Gebhardt P, Grosse-Gehling P, Würbach L, Irmler I, Preusche S, et al. Implementation of 89Zr production and in vivo imaging of B-cells in mice with 89Zr-labeled anti-B-cell antibodies by small animal PET/CT. Appl Radiat Isot. 2011;69:852–7.CrossRef
18.
Perk LR, Vosjan MJWD, Visser GWM, Budde M, Jurek P, Kiefer GE, et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging. 2009;37:250–9.PubMedCrossRef
19.
Vosjan MJWD, Perk LR, Visser GWM, Budde M, Jurek P, Kiefer GE, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739–43.PubMedCrossRef
20.
Tinianow JN, Gill HS, Ogasawara A, Flores JE, Vanderbilt AN, Luis E, et al. Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol. 2010;37:289–97.PubMedCrossRef
21.
Börjesson PKE, Jauw YWS, Boellaard R, De Bree R, Comans EFI, Roos JC, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133–40.PubMedCrossRef
22.
Perk LR, Stigter-van Walsum M, Visser GWM, Kloet RW, Vosjan MJWD, Leemans CR, et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008;35:1857–67.PubMedCrossRef
23.
Brouwers A, Verel I, Van Eerd J, Visser GWM, Steffens MG, Oosterwijk E, et al. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm. 2004;19:155–63.PubMedCrossRef
24.
Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304–10.PubMedCrossRef
25.
Hoeben BAW, Kaanders JHAM, Franssen GM, Franssen GM, Troost EGC, Rijken PFJW, et al. PET imaging of hypoxia with 89Zr-labeled cG250-F(ab′)2 in head and neck tumors. J Nucl Med. 2010;51:1076–83.PubMedCrossRef
26.
Heskamp S, Van Laarhoven HW, Molkenboer-Kuenen JD, Franssen GM, Versleijen-Jonkers YM, Oyen WJ, et al. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med. 2010;51:1565–72.PubMedCrossRef
27.
Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for ImmunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51:1293–300.PubMedCrossRef
28.
Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, et al. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 Immuno-PET. J Nucl Med. 2011;52:1–8.CrossRef
29.
Hong H, Severin GW, Yang Y, Engle JW, Zhang Y, Bernhardt TE, et al. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging. 2011. doi:10.​1007/​s00259-011-1930-x.
30.
Perk LR, Visser GWM, Vosjan MJWD, Stigter-van Walsum M, Tijink BM, Leemans CR, et al. 89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med. 2005;46:1898–906.PubMed
31.
Aerts HJWL, Dubois L, Perk L, Vermaelen P, Van Dongen GAMS, Wouters BG, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50:123–31.PubMedCrossRef
32.
Perk LR, Visser OJ, Stigter-van Walsum M, Vosjan MJWD, Visser GWM, Zijlstra JM, et al. Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:1337–45.PubMedCrossRef
33.
Muylle K, Azerad MA, Perk LR, Meuleman N, Delrieu V, Ghanem G, et al. Immuno-PET/CT imaging with Zr-89-rituximab as a prelude for radioimmunotherpy with Y-90-rituximab in patients with relapsed CD20+ B cell non-Hodkin’s lymphoma. Ann Oncol. 2008;19:179–80.
34.
Nagengast WB, De Vries EG, Hospers GA, Mulder NH, De Jong JR, Hollema H, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313–9.PubMedCrossRef
35.
Nagengast WB, De Korte MA, Oude Munnink TH, Timmer-Bosscha H, Den Dunnen WF, Hollema H, et al. Lub-de Hooge M, Schröder CP, De Vries EGE. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010;51:761–7.PubMedCrossRef
36.
Dijkers ECF, Kosterink JGW, Rademaker AP, Perk LR, Van Dongen GAMS, Bart J, et al. Development and characterization of clinical grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974–81.PubMedCrossRef
37.
Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, De Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586–92.PubMedCrossRef
38.
Holland JP, Caldas-Lopes E, Divilov V, Longo Va, Taldone T, Zatorska D, et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using 89Zr-DFO-trastuzumab. PLoS One. 2010;5:e8859.PubMedCrossRef
39.
Glekas AP, Pillarsetty NK, Punzalan B, Khan N, Smith-Jones P, Larson SM. In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib. J Nucl Med. 2011;52:1301–7.PubMedCrossRef
40.
Kil K-E, Ding Y-S, Lin K-S, Alexoff D, Kim SW, Shea C, et al. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol. 2007;34:153–63.PubMedCrossRef
41.
Wang J-Q, Gao M, Miller KD, Sledge GW, Zheng Q-H. Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor kinase. Bioorg Med Chem Lett. 2006;16:4102–6.PubMedCrossRef
42.
Holt DP, Ravert HT, Dannals RF, Pomper MG. Synthesis of [11C]gefitinib for imaging epidermal growth factor receptor tyrosine kinase with positron emission tomography. J Lab Compd Radiopharm. 2006;49:883–8.CrossRef
43.
Zhang M-R, Kumata K, Hatori A, Takai N, Toyohara J, Yamasaki T, et al. [11C]Gefitinib [11C]Iressa: radiosynthesis, in vitro uptake, and in vivo imaging of intact fibrosarcoma. Mol Imaging Biol. 2010;12:181–91.PubMedCrossRef
44.
Seimbille Y, Phelps ME, Czernin J, Silvermann DHS. Fluorine-18 labeling of 6,7-disubstituted anilinoquinazoline derivatives for positron emission tomography (PET) imaging of tyrosine kinase receptors: synthesis of [18F]-Iressa and related molecular probes. J Label Compd Radiopharm. 2005;48:829–43.CrossRef
45.
Su H, Seimbille Y, Feri GZ, Bodenstein C, Fueger B, Kim KJ, et al. Evaluation of [18F]-gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging. 2008;35:1089–99.PubMedCrossRef
46.
Wang J-Q, Miller KD, Sledge GW, Zheng Q-H. Synthesis of [18F] SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Bioorg Med Chem Lett. 2005;15:4380–3.PubMedCrossRef
47.
Memon AA, Jakobsen S, Dagnaes-Hanen F, Sorensen BS, Keiding S, Nexo E. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res. 2009;69:873–8.PubMedCrossRef
48.
Basuli F, Wu H, Li C, Shi Z-D, Sulima A, Griffith GL. A first synthesis of 18F-lapatinib: a potential tracer for positron emission tomography imaging of Erb1/Erb2 tyrosine kinase activity. J Label Compd Radiopharm. 2011;54:633–6.CrossRef
49.
Asakawa C, Ogawa M, Kumata K, Fujinaga M, Kato K, Yamasaki T, et al. [11C]Sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice. Bioorg Med Chem Lett. 2011;21:2220–3.PubMedCrossRef
50.
Verel I, Visser GWM, Van Dongen GAMS. The promise of immuno-PET in radioimmunotherapy. J Nucl Med. 2005;46 Suppl 1:164S–71.PubMed
51.
52.
McKabe K, Wu AM. Positive progress in immunoPET—not just a coincidence. Cancer Biother Radiopharm. 2010;25:253–61.CrossRef
53.
Börjesson PKE, Jauw YWS, de Bree R, Roos JC, Castelijns JA, Leemans CR, et al. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50:1828–36.PubMedCrossRef
54.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.PubMedCrossRef
Metadata
Title
PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET
Authors
Guus A. M. S. van Dongen
Alex J. Poot
Danielle J. Vugts
Publication date
01-06-2012
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0316-4

Other articles of this Issue 3/2012

Tumor Biology 3/2012 Go to the issue

Research Article

Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients

Research Article

Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC)

Review

Novel aspect of chemophototherapy in treatment of cancer

Research Article

Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus

Research Article

DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate: a curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment

Research Article

Analysis of the expression of angiotensin II type 1 receptor and VEGF in endometrial adenocarcinoma with different clinicopathological characteristics
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits